Back to Newsroom

Breast Cancer Screening Guidelines Explained: When to Start, How Often, and What to Know About Your Risk

Tanya Gupta, M.D.

Medical Director

A signpost with five arrows asking: Start at 40? Annually or every 2 years? Add ultrasound? Add MRI? Is it recommended or not?

Different organizations recommend different screening schedules. Here's how to understand the guidelines and make informed decisions about your breast health.

If you've ever wondered whether you should get a mammogram every year or every two years, you're not alone. Even leading medical organizations have different recommendations.

The good news? These guidelines share an important goal: helping women detect breast cancer early, when treatment may be more effective.

According to the American Cancer Society, approximately 1 in 8 U.S. women will develop breast cancer during her lifetime.1 Yet your individual risk and the screening approach that makes sense for you depends on more than age alone.

Understanding the recommendations is a powerful first step toward taking control of your breast health.

What Do the Major Breast Cancer Screening Guidelines Recommend?

For women at average risk, most major organizations support beginning mammography discussions or screening by age 40. The biggest differences involve how frequently to screen.

OrganizationWhen to startHow often
United States Preventive Services Task Force (USPSTF)Age 40Every 2 years through 74
American College of Radiology (ACR)Age 40Every year
National Comprehensive Cancer Network (NCCN)Age 40Every year
American Cancer Society (ACS)Ages 40–44 optional; 45 recommendedAnnually ages 45–54; annually or biennially from 55
American College of Obstetricians and Gynecologists (ACOG)Age 40Every 1–2 years
American College of Physicians (ACP)Ages 40–49 through shared decision-makingEvery 2 years if screening is chosen; every 2 years ages 50–74

Sources: Recent guidance and updates from ACOG (2025),2 ACR (2025),3 ACP (2026),4 ACS (2026),5 and current USPSTF6 and NCCN7 recommendations.

Why the differences? Organizations weigh the benefits of detecting cancer earlier against potential screening drawbacks, including false-positive results, additional testing, and overdiagnosis.

The takeaway: Guidelines are a starting point for discussions with your provider on your personalized screening plan.

How Does Breast Density Affect Screening?

Breast density is one of the most important factors to understand when reviewing your mammogram results.

According to the FDA, approximately half of women over age 40 have dense breast tissue.8 Dense breasts contain more fibrous and glandular tissue relative to fatty tissue.

This matters for two reasons:

  • Dense tissue can make cancers harder to see on mammograms because both dense tissue and tumors appear white.

  • Higher breast density is associated with an increased risk of developing breast cancer.

Since September 2024, FDA regulations have required mammography facilities to notify patients about their breast density.8

If your results indicate dense breasts, it doesn't mean you have cancer. It means you have additional information that may influence your screening decisions.

Should Women with Dense Breasts Receive Additional Screening?

Recommendations vary.

The NCCN advises considering supplemental screening for women with heterogeneously or extremely dense breasts. The ACR identifies MRI and ultrasound as potentially appropriate in certain screening situations.37

The USPSTF, however, concludes that evidence remains insufficient to recommend for or against supplemental ultrasound or MRI solely because of dense breasts.6

This is an important distinction: insufficient evidence is not the same as a recommendation against additional screening.

Your overall risk, breast density, and medical history can help determine whether additional imaging may be appropriate.

What If You're at Higher Risk for Breast Cancer?

Average-risk guidelines may not provide enough guidance for women with certain risk factors.

These include:

  • A strong family history of breast or ovarian cancer

  • Inherited genetic variants, such as BRCA1 or BRCA2

  • Previous radiation treatment to the chest at a young age

  • Certain high-risk findings on previous breast biopsies

  • A calculated lifetime breast cancer risk of approximately 20% or greater

For many women at high risk, the ACS recommends annual breast MRI plus mammography, typically beginning around age 30. The ACR also recommends earlier MRI screening for certain high-risk groups, sometimes beginning between ages 25 and 30.35

Your clinician may recommend a formal risk assessment, genetic counseling, or a screening schedule that begins earlier than age 40.

Beyond Mammography: Understanding Your Options

Mammography remains the foundation of routine breast cancer screening. Depending on your risk and breast density, your healthcare provider may also discuss 3D mammography, ultrasound, or MRI.

Emerging blood-based technologies are also being developed to provide additional information that may support breast health decisions.

Certitude® is a blood-based test designed to provide another layer of insight for women with dense breasts and support conversations between patients and their healthcare providers.

Certitude does not replace mammography, recommended supplemental imaging, or diagnostic follow-up. Blood-based testing is not currently included as a substitute for established breast cancer screening in the major guidelines discussed here.

The goal is informed care: understanding which options are appropriate for your individual circumstances.

Five Questions to Ask Your Doctor About Breast Cancer Screening

Your next appointment is an opportunity to create a plan tailored to you.

  1. What is my personal lifetime risk of breast cancer? Ask whether a formal risk assessment would be helpful.

  2. Do I have dense breasts? Review your mammogram report and what your density category means.

  3. Should I be screened annually or every two years? Discuss the benefits and potential drawbacks of each approach.

  4. Would additional screening benefit me? Ask whether MRI, ultrasound, or other options are appropriate.

  5. What should my screening plan look like over the next several years? Confirm when to schedule your next exam and what changes would warrant earlier evaluation.

If you notice a new lump, nipple discharge, or another concerning breast change, contact your healthcare provider rather than waiting for your next routine screening.

Your Screening Plan Should Be as Individual as You Are

Breast cancer screening guidelines offer valuable direction, but they cannot capture every woman's unique circumstances.

Whether you're approaching your first mammogram, navigating dense breast results, or exploring additional options because of family history, the most important step is having an informed conversation with your healthcare provider.

Knowing your risk, understanding your breast density, and asking the right questions can help you move forward with greater confidence.

Less uncertainty. More confidence.

Learn more about Certitude and how a blood-based option may support breast health conversations at certitudetest.com.

Footnotes

  1. Key Statistics for Breast Cancer | American Cancer Society ↩

  2. Breast Cancer Risk Assessment and Screening in Average-Risk Women | ACOG - College ↩

  3. ACR Appropriateness Criteria® Female Breast Cancer Screening: 2025 Update - Journal of the American College of Radiology ↩ ↩2 ↩3

  4. Screening for Breast Cancer in Asymptomatic, Average-Risk Adult Females: A Guidance Statement From the American College of Physicians (Version 2) | Annals of Internal Medicine ↩

  5. ACS Breast Cancer Screening Guidelines | American Cancer Society ↩ ↩2

  6. Recommendation: Breast Cancer: Screening | United States Preventive Services Taskforce ↩ ↩2

  7. NCCN Guidelines for Patients: Breast Cancer Screening and Diagnosis ↩ ↩2

  8. Understanding Breast Density | FDA ↩ ↩2

Certitude

1000 Westgate Drive
St. Paul, MN 55114

© Astrin Biosciences 2025. All rights reserved.

The Certitude Test is a laboratory developed test (LDT) from Astrin Biosciences Inc., and is performed by Clinical Laboratory Improvement Amendments (CLIA) certified, College of American Pathologists (CAP) accredited laboratories qualified to conduct high-complexity clinical testing and is only intended for use consistent with applicable CLIA and CAP requirements. The Certitude test performance characteristics were validated by Astrin Biosciences following CAP and CLIA regulations. When offered as an LDT, the Certitude Test has not been cleared or approved by the U.S. Food and Drug Administration (FDA).